| AlphaValue Corporate Services has been commissioned and paid for by the covered companies and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II. |
RESEARCH PUBLICATIONS
CROSSJECT |
||||
 |
COUNTRY | SECTOR | INDUSTRY | MARKET CAP. |
 France |
Supergenerics | Pharma | €120m | |
| DESCRIPTION | ||||
| We regard Crossject as a new entrant in the speciality pharma field. Its differentiating feature is its delivery mechanism, Zeneo, a pretty unique needle-free injection system. Crossject has completed clinical trials on a first well-known molecule, Methotrexate, with another six to go in the pipeline. Zeneo is the fruit of over 15 years of R&D. It is an automatic single-use pre-filled needle-free injection device to be used, for example, on the thigh or abdomen. The technology is based on a high-pressure injection allowing a drug to be administered rapidly (1/10 sec) into the tissue. | ||||